| | | | January 2023 Clinical Update: NCCN Updates Guidelines for Treatment of Prostate Cancer
| | The National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer focus on the screening, diagnosis, staging, treatment, and management considering individual risk assessment.
These updated guidelines include criteria for further genetic risk evaluation using a hereditary cancer panel for hereditary cancer syndromes: · Close family history of known pathogenic variations or cancer, · Metastatic, regional, very-high risk localized, high-risk localized prostate cancer, OR · Tumors with certain histological characteristics.
Germline testing should be considered in appropriate individuals where it will likely impact the treatment, clinical trial options and risk management. The recommended panels should contain BRCA1, BRCA2, ATM, PALB2, CHEK2, MLH1, MSH2, MSH6, and PMS2.
Genetics Institute of America’s GIAnomics™ Oncology Germline Panel includes all the recommended predisposition genes for Prostate cancer. GIA is committed to exceeding the standards put forth by prestigious organizations, like NCCN, and ensuring that the panels we offer support your medical needs and your patient’s health and safety. | | | | Have you Seen This?:
Is Somatic Tumor Testing Sufficient for Proper Patient Care?Somatic tumor genetic testing is becoming more common in oncology to understand a patient’s prognosis, eligibility for clinical trials, and targeted treatment opportunities. This type of testing isolates tumor tissue and identifies variants associated with cancerous growth. However, clinicians are not always referring patients for additional germline testing after receiving somatic testing results. Read more >>
| | | |
It's All in the Genes:
ATM Pathogenic Variants in Cancer RiskATM codes for a kinase, which is found in the cell nucleus. Its primary function is to control how fast cells proliferate within the body, as well as aid in DNA repair.1 ATM plays a vital role in the development of key body systems including the nervous system and immune system. Diminished function of the ATM protein could result in serious health conditions, including ataxia-telangiectasia and various types of cancer. 1 Read more >>
| | | | Changing Corporate Culture: CityHouse 5K and Providing Care for Single Mothers Since being established in 2014, CityHouse of Delray Beach, Florida provides long-term, transformational assistance to mothers and their children. They help single mothers in need have better opportunities to develop healthy lifestyles, which enables them to provide sustainable, loving and proper care for their children. Read more >> | | | | | | | | Enroll your Practice in GH-101! | | Genetics Institute of America is actively recruiting practices to join our study, GH-101! The objective of this study is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics by identifying DNA and RNA variants in persons with chronic disease. We are looking for Physicians and Physician Groups that currently treat patients with a chronic disease including: cancer, cardiac conditions, diabetes, kidney disease, PTSD. Getting your practice involved is easy and not only gets patients the individualized health information they need but allows your practice to be on the cutting edge of genetic research. | | | | | | Thank you for the trust and confidence you have placed in our team here at the Genetics Institute of America. This monthly newsletter is our primary method of communicating to you important information about our testing and assays, general information about the Genetics Institute, as well as information impacting patient care and safety. If you would like to have another person in your practice receive these updates, please forward this to them so that they can subscribe.
 Ana Perez-Miranda, PhD, MDxT (AAB), MB (ASCP) Laboratory Manager and Molecular Diagnostics Supervisor Genetics Institute of America | | | | | | | | | | GIA Lab News is an educational service of Genetics Institute of America.
Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote the longevity and quality of life outcomes. Our determination and research allow us to provide next generation DNA sequencing to deliver customized testing for identified genetic related cancers and other diseases. | | | | | | 4733 W. Atlantic Ave, Suite C16 Delray Beach, FL 33445 Phone: (833) 4GENLAB or (833) 443-6522 HIPAA Fax: (561) 354-5369
| | You are receiving this email because you opted into receiving communications from Genetics Institute of America online or verbally on the phone, and/or maintain a professional relationship with our laboratory. From time to time, we’ll send newsletters, blog articles, and other educational clinical updates to our subscribers. We hope you find them useful. If not, you can unsubscribe from our list here.
Who do you know that needs to know? Forward this email Did someone forward this to you? Subscribe
Want to change how you receive these emails?
You can Unsubscribe or Update your preferences.
© 2023 Genetics Institute of America. All Rights Reserved.
| | | | | | | |
.png)
